I

118TH CONGRESS
1ST SESSION

H. R. 5850

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 29, 2023

Mr. MANN (for himself and Mr. MOOLENAAR) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

A BILL

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. NULLIFICATION OF REMS MODIFICATIONS FOR MIFEPRISTONE; NO FEDERAL FUNDING TO IMPLEMENT REMS FOR MIFEPRISTONE.

(a) IN GENERAL.—The modifications made by the Food and Drug Administration on January 3, 2023, to

the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone are hereby nullified.

(b) PROHIBITION ON FEDERAL FUNDS.—No Federal funds may be used to establish, implement, or enforce—

(1) any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a); or

(2) any non-enforcement or enforcement discretion policy for any provision of a risk evaluation and mitigation strategy under such section for mifepristone.

○